An overview of novel therapies in advanced clinical testing for acute myeloid leukemia

References

• Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392(10147):593–606.
   PubMed Web of Science ®Google Scholar
• Shallis RM, Wang R, Davidoff A, et al. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019;36:70–87.
   PubMed Web of Science ®Google Scholar
• Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136–1152.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Kadia T, DiNardo C, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11(2):1–25.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629.
   PubMed Web of Science ®Google Scholar
• Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135(24):2137–2145.
   PubMed Web of Science ®Google Scholar
• Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345–1377.
   PubMed Web of Science ®Google Scholar
• Venugopal S, Bar-Natan M, Mascarenhas JO. JAKs to STATs: a tantalizing therapeutic target in acute myeloid leukemia. Blood Rev. 2020 Mar;40:100634.
   PubMed Web of Science ®Google Scholar
• Bloomfield CD, Estey E, Pleyer L, et al. Time to repeal and replace response criteria for acute myeloid leukemia? Blood Rev. 2018 Sep;32(5):416–425.
   PubMed Web of Science ®Google Scholar
• Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017 Aug 10;130(6):722–731.
   PubMed Web of Science ®Google Scholar
• Hourigan CS, Karp JE. Minimal residual disease in acute myeloid leukaemia. Nat Rev Clin Oncol. 2013;10(8):460–471.
   PubMed Web of Science ®Google Scholar
• Short NJ, Ravandi F. How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia? Haematologica. 2019;104(8):1532.
   PubMed Web of Science ®Google Scholar
• Short NJ, Zhou S, Fu C, et al. Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis. JAMA Oncol. 2020 Dec 1;6(12):1890–1899.
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood J Am Soc Hematol. 2017;129(4):424–447.
   Google Scholar
• DeWolf S, Tallman MS. How I treat relapsed or refractory AML. Blood. 2020;136(9):1023–1032.
   PubMed Web of Science ®Google Scholar
• Ramos NR, Mo CC, Karp JE, et al. Current approaches in the treatment of relapsed and refractory acute myeloid leukemia. J Clin Med. 2015;4(4):665–695.
   PubMed Web of Science ®Google Scholar
• Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352(3):254–266.
   PubMed Web of Science ®Google Scholar
• Grisendi S, Mecucci C, Falini B, et al. Nucleophosmin and cancer [Review Article]. Nat Rev Cancer. 2006Jan07; 6:493. online
   PubMed Web of Science ®Google Scholar
• Falini B, Brunetti L, Sportoletti P, et al. NPM1-mutated acute myeloid leukemia: from bench to bedside. Blood. 2020;136(15):1707–1721.
   PubMed Web of Science ®Google Scholar
• Brunetti L, Gundry MC, Sorcini D, et al. Mutant NPM1 maintains the leukemic state through HOX expression. Cancer Cell. 2018;34(3):499–512. e9.
   PubMed Web of Science ®Google Scholar
• Day MA, Sergeev P, Heckman CA, et al. Preclinical activity of selective syk inhibitors, entospletinib and lanraplenib, alone or combined with targeted agents in ex vivo aml models with diverse mutational backgrounds. Blood. 2021;138:3356.
   Web of Science ®Google Scholar
• Tyner JW, Tognon CE, Bottomly D, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018;562(7728):526–531.
   PubMed Web of Science ®Google Scholar
• Uckelmann HJ, Kim SM, Antonissen NJ, et al. MLL-Menin inhibition reverses pre-leukemic progenitor self-renewal induced by NPM1 mutations and prevents AML development. Blood. 2018;132:546.
   Web of Science ®Google Scholar
• Swaminathan M, Bourgeois W, Armstrong SA, et al. Menin inhibitors in acute myeloid leukemia—what does the future hold? Cancer J. 2022;28(1):62–66.
   PubMed Web of Science ®Google Scholar
• Walker AR, Byrd JC, Blachly JS, et al. Entospletinib in combination with induction chemotherapy in previously untreated acute myeloid leukemia: response and predictive significance of HOXA9 and MEIS1 expressionentospletinib+ induction chemotherapy in untreated AML. Clin Cancer Res. 2020;26(22):5852–5859.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Cortes JE, Minden MD, et al. A phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of entospletinib in combination with intensive induction and consolidation chemotherapy in adults with newly diagnosed nucleophosmin 1-mutated acute myeloid leukemia. Blood. 2021 Nov 23;138:1282.
   PubMed Web of Science ®Google Scholar
• Issa GC, Ravandi F, DiNardo CD, et al. Therapeutic implications of menin inhibition in acute leukemias. Leukemia. 2021;35(9):2482–2495.
   PubMed Web of Science ®Google Scholar
• Krivtsov AV, Figueroa ME, Sinha AU, et al. Cell of origin determines clinically relevant subtypes of MLL-rearranged AML. Leukemia. 2013;27(4):852–860.
   PubMed Web of Science ®Google Scholar
• Faber J, Krivtsov AV, Stubbs MC, et al. HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood J Am Soc Hematol. 2009;113(11):2375–2385.
   Google Scholar
• Kühn MW, Armstrong SA. Designed to kill: novel menin-MLL inhibitors target MLL-rearranged leukemia. Cancer Cell. 2015;27(4):431–433.
   PubMed Web of Science ®Google Scholar
• Uckelmann HJ, Kim SM, Wong EM, et al. Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia. Science. 2020;367(6477):586–590.
   PubMed Web of Science ®Google Scholar
• Wang ES, Altman JK, Pettit K, et al. Preliminary data on a phase 1/2A first in human study of the menin-KMT2A (MLL) inhibitor KO-539 in patients with relapsed or refractory acute myeloid leukemia. Blood. 2020;136:7–8.
   Google Scholar
• Kura oncology receives FDA authorization to proceed with phase 1b study of KO-539 in acute myeloid leukemia [internet]. GLOBE NEWSWIRE; 2022. [cited 2022 Jan 20]. Available from: https://ir.kuraoncology.com/news-releases/news-release-details/kura-oncology-receives-fda-authorization-proceed-phase-1b-study
   Google Scholar
• Stein EM, Aldoss I, DiPersio JF, et al. Safety and efficacy of menin inhibition in patients (Pts) with MLL-rearranged and NPM1 mutant acute leukemia: a phase (Ph) 1, first-in-human study of SNDX-5613 (AUGMENT 101). Blood. 2021;138:699.
   Google Scholar
• Kadia TM, Jain P, Ravandi F, et al. TP53 mutations in newly diagnosed acute myeloid leukemia: clinicomolecular characteristics, response to therapy, and outcomes. Cancer. 2016;122(22):3484–3491.
   PubMed Web of Science ®Google Scholar
• Shallis RM, Bewersdorf JP, Stahl MF, et al. Are we moving the needle for patients with TP53-mutated acute myeloid leukemia? Cancers (Basel). 2022;14(10):2434.
   PubMed Web of Science ®Google Scholar
• Short NJ, Montalban-Bravo G, Hwang H, et al. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Adv. 2020;4(22):5681–5689.
   PubMed Web of Science ®Google Scholar
• Venugopal S, Shoukier M, Konopleva M, et al. Outcomes in patients with newly diagnosed TP53‐mutated acute myeloid leukemia with or without venetoclax‐based therapy. Cancer. 2021;127(19):3541–3551.
   PubMed Web of Science ®Google Scholar
• Kim K, Maiti A, Loghavi S, et al. Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax. Cancer. 2021;127(20):3772–3781.
   PubMed Web of Science ®Google Scholar
• Saha MN, Qiu L, Chang H. Targeting p53 by small molecules in hematological malignancies. J Hematol Oncol. 2013;6(1):1–9.
   PubMedGoogle Scholar
• Maslah N, Salomao N, Drevon L, et al. Synergistic effects of PRIMA-1Met (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia. Haematologica. 2020;105(6):1539.
   PubMed Web of Science ®Google Scholar
• Sallman DA, DeZern AE, Garcia-Manero G, et al. Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes. J clin oncol. 2021;39(14):1584.
   PubMed Web of Science ®Google Scholar
• Sallman DA, Komrokji RS, DeZern AE, et al. Long term follow-up and combined phase 2 results of eprenetapopt (APR-246) and azacitidine (AZA) in patients with TP53 mutant myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia (AML). Blood. 2021 Nov 23;138:246.
   PubMed Web of Science ®Google Scholar
• Aprea therapeutics announces results of primary endpoint from phase 3 trial of eprenetapopt in TP53 mutant myelodysplastic syndromes (MDS) [Internet]. WWW: GLOBE NEWSWIRE; December 28, 2020 Available from: https://ir.aprea.com/news-releases/news-release-details/aprea-therapeutics-announces-results-primary-endpoint-phase-3
   Google Scholar
• Mishra A, Tamari R, DeZern AE, et al. Eprenetapopt plus azacitidine after allogeneic hematopoietic stem-cell transplantation for TP53-mutant acute myeloid leukemia and myelodysplastic syndromes. J clin oncol. 2022;JCO:22.00181.
   Google Scholar
• Thorsson V, Gibbs DL, Brown SD, et al. The immune landscape of cancer. Immunity. 2018;48(4):812–830.
   PubMed Web of Science ®Google Scholar
• Schwartz S, Patel N, Longmire T, et al. Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor. Adv Immunol. 2022;2. 10.1093/immadv/ltac019.
   Google Scholar
• Kikushige Y, Shima T, S-i T, et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell. 2010;7(6):708–717.
   PubMed Web of Science ®Google Scholar
• Brunner AM, Esteve J, Porkka K, et al. Efficacy and safety of sabatolimab (mbg453) in combination with hypomethylating agents (hmas) in patients (pts) with very high/high-risk myelodysplastic syndrome (vhr/hr-mds) and acute myeloid leukemia (aml): final analysis from a phase ib study. Blood. 2021;138:244.
   Web of Science ®Google Scholar
• Zeidan AM, Esteve J, Giagounidis A, et al. The STIMULUS program: clinical trials evaluating sabatolimab (MBG453) combination therapy in patients (Pts) with higher-risk myelodysplastic syndromes (HR-MDS) or acute myeloid leukemia (AML). Blood. 2020;136(Supplement 1):45–46.
   Google Scholar
• Mitchell K, Steidl U. Targeting immunophenotypic markers on leukemic stem cells: how lessons from current approaches and advances in the leukemia stem cell (LSC) model can inform better strategies for treating acute myeloid leukemia (AML). Cold Spring Harb Perspect Med. 2020;10(1):a036251.
   PubMed Web of Science ®Google Scholar
• Chao MP, Weissman IL, Majeti R. The CD47–SIRPα pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol. 2012;24(2):225–232.
   PubMed Web of Science ®Google Scholar
• Sallman DA, Asch AS, Al Malki MM, et al. The first-in-class anti-CD47 antibody magrolimab (5F9) in combination with azacitidine is effective in MDS and AML patients: ongoing phase 1b results. Blood. 2019;134(Supplement_1):569.
   Web of Science ®Google Scholar
• Garcia-Manero G, Daver NG, Xu J, et al. Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): the phase 3, randomized, ENHANCE study. J clin oncol. 2021 May 20;39(15_suppl): TPS7055–TPS7055.
   Web of Science ®Google Scholar
• Daver N, Konopleva M, Maiti A, et al. Phase I/II study of azacitidine (AZA) with venetoclax (VEN) and magrolimab (Magro) in patients (pts) with newly diagnosed older/unfit or high-risk acute myeloid leukemia (AML) and relapsed/refractory (R/R) AML. Blood. 2021 Nov 23;138:371.
   Web of Science ®Google Scholar
• Daver N, Venugopal S, Ravandi F. FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm. Blood Cancer J. 2021 May 27;11(5):104.
   PubMed Web of Science ®Google Scholar
• Quizartinib prolonged survival vs placebo plus intensive induction and consolidation therapy followed by single-agent continuation in patients aged 18-75 years with newly diagnosed Flt3-Itd+ AML. In: Erba H, Montesinos P, Vrhovac R, et al., editor. Abstract Book for the 27th Congress of the European Hematology Association HemaSphere2022, Vienna,Austria. p. 1–4130.
   Google Scholar
• Stone RM, Manley PW, Larson RA, et al. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. Blood Adv. 2018 Feb 27;2(4):444–453.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378(25):2386–2398.
   PubMed Web of Science ®Google Scholar
• Watts JM, Baer MR, Yang J, et al. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. Lancet Haematol. 2023;10(1):e46–58.
   PubMed Web of Science ®Google Scholar
• Stein EM, DiNardo CD, Fathi AT, et al. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. Blood. 2021 Apr 1;137(13):1792–1803.
   PubMed Web of Science ®Google Scholar
• Venugopal S, Maiti A, DiNardo CD, et al. Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia. Am J Hematol. 2021;96(5):E154–E157.
   PubMed Web of Science ®Google Scholar
• Pollyea DA, DiNardo CD, Arellano ML, et al. Impact of venetoclax and azacitidine in treatment-naïve patients with acute myeloid leukemia and IDH1/2 mutations. Clin Cancer Res. 2022;28(13):2753–2761.
   PubMed Web of Science ®Google Scholar
• Desikan SP, Daver N, DiNardo C, et al. Resistance to targeted therapies: delving into FLT3 and IDH. Blood Cancer J. 2022 Jun 09;12(6):91.
   PubMed Web of Science ®Google Scholar
• Lachowiez CA, Garcia JS, Borthakur G, et al. A phase Ib/II study of ivosidenib with venetoclax ± azacitidine in IDH1-mutated hematologic malignancies. J clin oncol. 2022;40(16_suppl):7018.
   Web of Science ®Google Scholar
• Mesbahi Y, Trahair TN, Lock RB, et al. Exploring the metabolic landscape of AML: from haematopoietic stem cells to myeloblasts and leukaemic stem cells. Front Oncol. 2022;12:807266.
   PubMed Web of Science ®Google Scholar
• Erbani J, Tay J, Barbier V, et al. Acute myeloid leukemia chemo-resistance is mediated by E-selectin receptor CD162 in bone marrow niches. Front Cell Dev Biol. 2020;8:668.
   PubMed Web of Science ®Google Scholar
• Muz B, Abdelghafer A, Markovic M, et al. Targeting E-selectin to tackle cancer using uproleselan. Cancers (Basel). 2021 Jan 18;13(2):335.
   PubMed Web of Science ®Google Scholar
• DeAngelo DJ, Jonas BA, Liesveld JL, et al. Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia. Blood. 2022;139(8):1135–1146.
   PubMed Web of Science ®Google Scholar
• Konopleva M, Letai A. BCL-2 inhibition in AML: an unexpected bonus? Blood. 2018 Sep 6;132(10):1007–1012.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Tiong IS, Quaglieri A, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020 Mar 12;135(11):791–803.
   PubMed Web of Science ®Google Scholar
• Nechiporuk T, Kurtz SE, Nikolova O, et al. The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells. Cancer Discov. 2019 Jul;9(7):910–925.
   PubMed Web of Science ®Google Scholar
• Wei AH, Roberts AW, Spencer A, et al. Targeting MCL-1 in hematologic malignancies: rationale and progress. Blood Rev. 2020 Nov;44:100672.
   PubMed Web of Science ®Google Scholar
• Perciavalle RM, Stewart DP, Koss B, et al. Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration. Nat Cell Biol. 2012 Apr 29;14(6):575–583.
   PubMed Web of Science ®Google Scholar
• Valentin R, Grabow S, Davids MS. The rise of apoptosis: targeting apoptosis in hematologic malignancies. Blood. 2018;132(12):1248–1264.
   PubMed Web of Science ®Google Scholar
• Zeidner JF, Lee DJ, Frattini M, et al. Phase I study of ALVOCIDIB FOLLOWED by 7+3 (cytarabine + daunorubicin) in newly diagnosed acute myeloid leukemia. Clin Cancer Res. 2021;27(1):60–69.
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Watts J, Radinoff A, et al. Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML. Leukemia. 2021 Jul;35(7):2119–2124.
   PubMed Web of Science ®Google Scholar
• Adès L, Girshova L, Doronin VA, et al. Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast percentage AML. Blood Adv. 2022;6:5132–5145.
   PubMed Web of Science ®Google Scholar
• Short NJ, Montalban-Bravo G, Alvarado Y, et al. Azacitidine, venetoclax and pevonedistat as frontline therapy for patients with secondary acute myeloid leukemia who are unfit for intensive chemotherapy: results from a phase i/ii study. Blood. 2021 Nov 23;138:2349.
   Google Scholar
• Kojima K, Konopleva M, Samudio IJ, et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood. 2005;106(9):3150–3159.
   PubMed Web of Science ®Google Scholar
• Konopleva M, Martinelli G, Daver N, et al. MDM2 inhibition: an important step forward in cancer therapy. Leukemia. 2020 Nov 01;34(11):2858–2874.
   PubMed Web of Science ®Google Scholar
• Khurana A, Shafer DA. MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388). Onco Targets Ther. 2019;12:2903–2910.
   PubMed Web of Science ®Google Scholar
• Konopleva MY, Röllig C, Cavenagh J, et al. Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial. Blood Adv. 2022 Jul 26;6(14):4147–4156.
   PubMed Web of Science ®Google Scholar
• Senapati J, Ishizawa J, Abbas HA, et al. P576: a Phase I/Ii study of milademetan (Ds3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia. HemaSphere. 2022;357439:P576.
   Google Scholar
• Venugopal S, Daver N, Ravandi F. An update on the clinical evaluation of antibody-based therapeutics in acute myeloid leukemia. Curr Hematol Malig Rep. 2021 Feb;16(1):89–96.
   PubMed Web of Science ®Google Scholar
• Pemmaraju N, Lane AA, Sweet KL, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019;380(17):1628–1637.
   PubMed Web of Science ®Google Scholar
• Togami K, Pastika T, Stephansky J, et al. DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance. J Clin Invest. 2019 Nov 1;129(11):5005–5019.
   PubMed Web of Science ®Google Scholar
• Lane AA, Stein AS, Garcia JS, et al. Safety and efficacy of combining tagraxofusp (sl-401) with azacitidine or azacitidine and venetoclax in a phase 1b study for cd123 positive AML, MDS, or BPDCN. Blood. 2021;138(Supplement 1):2346.
   Google Scholar
• Uy GL, Aldoss I, Foster MC, et al. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood. 2021;137(6):751–762.
   PubMed Web of Science ®Google Scholar
• Vadakekolathu J, Minden MD, Hood T, et al. Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia. Sci Transl Med. 2020 Jun 3;12:546.
   Web of Science ®Google Scholar
• MacroGenics provides update on corporate progress and 2021 financial results [internet]. https://www.globenewswire.com/en/news-release/2022/02/24/2391879/0/en/MacroGenics-Provides-Update-on-Corporate-Progress-and-2021-Financial-Results.html Feb/24/2022[cited 2023 Aug 01]
   Google Scholar
• Daver N, Aribi A, Montesinos P, et al. Safety and efficacy from a phase 1b/2 study of IMGN632 in combination with azacitidine and venetoclax for patients with CD123-positive acute myeloid leukemia. Blood. 2021;138(Supplement 1):372.
   Google Scholar